GCT announces first subjects screened in the Russian part of a multinational ulcerative colitis trial. Locally, the study is conducted in 6 investigative sites on behalf of a US Sponsor developing an innovative biologic product to treat this debilitating condition.
Updated: March 17, 2017
Share this:
Permanent link: https://2022.gctrials.com/news/first-patients-in-ibd-trial/
BD Contact:
Natalia Katsnelson
Senior Director, Business Development
bd@gctrials.com
telephone: +1 609 921 6868
GMT – 05:00 Eastern time
256 Bunn Drive, Suite 6, Princeton, NJ 08540
BD Contact:
Aleksandr Stiblo
Director, Business Development
bd@gctrials.com
telephone: +7 812 703 0008
GMT + 05:00 Moscow time
23/Z Prof. Popova ul, St. Petersburg, 197376 Russia